Foxy-5
DCTPepD ID DCTPepD0037
Active Ingredients Foxy-5
Description A formylated, six amino acid, Wnt5a-derived peptide and wnt-5a mimetic with potential anti-metastatic activity. Upon intravenous administration, Wnt-5a mimic hexapeptide foxy-5 binds to and activates the wnt-5a receptors, Frizzled-2 and -5, which activates wnt-5a-mediated signaling. Increased wnt-5a signaling may inhibit endothelial tumor cell migration and invasion. This may decrease metastasis of susceptible tumor cells. However, foxy-5 does not affect tumor cell proliferation or apoptosis. Foxy-5 lacks a heparan sulfate-binding domain and contains a formyl group on its NH2-terminal methionine residue which decreases in vivo degradation. Decreased expression of wnt-5a protein is associated with increased motility of certain tumor cell types.
Synonyms Wnt-5a Mimic Hexapeptide Foxy-5; Foxy-5
Disease Prostate Cancer, Colorectal Cancer, Metastatic Colon Cancer, Metastatic Breast Cancer, Metastatic Prostate Cancer
Classification
Peptide and derivative
Structure Information
Molecular Formula C26H42N6O12S2
Molecular Weight 694.8
Active Sequence MDGCEL
Sequence Length 6
Modification C-terminal HCO
IUPAC Name (2S)-2-[[(2S)-4-carboxy-2-[[(2R)-2-[[2-[[(2S)-3-carboxy-2-[[(2S)-2-formamido-4-methylsulfanylbutanoyl]amino]propanoyl]amino]acetyl]amino]-3-sulfanylpropanoyl]amino]butanoyl]amino]-4-methylpentanoic acid
InChI InChI=1S/C26H42N6O12S2/c1-13(2)8-17(26(43)44)32-24(41)15(4-5-20(35)36)30-25(42)18(11-45)29-19(34)10-27-22(39)16(9-21(37)38)31-23(40)14(28-12-33)6-7-46-3/h12-18,45H,4-11H2,1-3H3,(H,27,39)(H,28,33)(H,29,34)(H,30,42)(H,31,40)(H,32,41)(H,35,36)(H,37,38)(H,43,44)/t14-,15-,16-,17-,18-/m0/s1
InChI_Key WFZPJYYCTSHDJI-ATIWLJMLSA-N
SMILES CC(C)C[C@H](NC([C@@H](NC([C@@H](NC(CNC([C@@H](NC([C@@H](NC=O)CCSC)=O)CC(O)=O)=O)=O)CS)=O)CCC(O)=O)=O)C(O)=O
External Codes
PubChem CID 44628955
DrugBank Accession Number DB13034
NCI Thesaurus Code C113435
UNII CBZ9UL0ARB GSRS
CAS 881188-51-8
Drug approval
Drug indication
Foxy-5 has been used in trials studying the treatment of Prostate Cancer, Colorectal Cancer, Metastatic Colon Cancer, Metastatic Breast Cancer, and Metastatic Prostate Cancer.
The drug is not approved.
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT02020291 | Phase I Dose Escalating Study to Evaluate the Safety, Tolerability, Anti-Tumour Activity and Pharmacokinetic and Pharmacodynamic Profiles of Foxy-5 in Patients With Metastatic Breast, Colon or Prostate Cancer | Metastatic Breast Cancer; Colorectal Cancer; Prostate Cancer | Phase 1 | Treatment |
| NCT02655952 | Phase Ib Dose Escalating Study to Evaluate the Safety, Tolerability and Pharmacodynamic Response of Foxy-5 in Patients With Metastatic Breast-, Colon- or Prostate Cancer | Metastatic Breast Cancer; Metastatic Colon Cancer; Metastatic Prostate Cancer | Phase 1 | Treatment |
| NCT03883802 | A Randomized, Multicentre, Open-Label Controlled Phase II Trial of Foxy-5 as Neo-Adjuvant Therapy in Subjects With Wnt-5a Low Colon Cancer | Colon Cancer | Phase 2 | Treatment |
More clinical information is obtained from ClinicalTrials.gov.
